This has led to an increasing trend towards bioprosthetic aortic valves for younger patients despite higher reoperation rates, in part driven by the low incidence of mortality (in some cases 2.5%) reported for redo AVR [ 3 , 18 ].
← all excerpts
Early results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement: the ARISE study and ARISE Registry data.
1
—
—